Proposals to Amend the Medicines (Child Safety) Regulations as Amended PDF Download

Author: Great Britain. Medicines Division
Publisher:
ISBN:
Category : Patent medicines
Languages : en
Pages : 2

View

Book Description

Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 0

View

Book Description

Author: United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Public Health and Welfare
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 354

View

Book Description
Committee Serial No. 89-43. Considers. H.R. 13884 and H.R. 14634, to clarify HEW authority for training personnel of state and local agencies for enforcement of food and drug laws. H.R. 13886, to limit the quantity of children's aspirin in one single retail package and to amend the Federal Hazardous Substances Labeling Act to ban hazardous toys and dangerous household articles. H.R. 14557, to authorize HEW to require that retail containers of drugs be secured by a safety closure. H.R. 14632, to require cautionary labeling on all drugs.

Author: Great Britain
Publisher:
ISBN: 9780110616438
Category :
Languages : en
Pages :

View

Book Description
Enabling power: Medicines act, 1968, ss. 87 (1), 88 (1) (2), 91 (2). Issued: 13.10.76. Made: 30.9.76. Laid: 13.10.76. Coming into force: 3.11.76. Effect: S.I. 1975/2000, amended.. Revoked by S.I. 2003/2317 (ISBN 0110474783)

Author: Stationery Office, The
Publisher:
ISBN: 9780110768779
Category :
Languages : en
Pages :

View

Book Description
Medicines (Child Safety) Amendment Regulations 1987

Author: Great Britain
Publisher:
ISBN: 9780110444024
Category : Drugs
Languages : en
Pages : 4

View

Book Description
Medicines (Child Safety) Amendment Regulations 1994

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309225493
Category : Medical
Languages : en
Pages : 432

View

Book Description
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.

Author: Susan Thaul
Publisher: Createspace Independent Pub
ISBN: 9781478201670
Category : Medical
Languages : en
Pages : 28

View

Book Description
On June 20, 2012, the House of Representatives passed, by voice vote and under suspension of the rules, S. 3187 (EAH), the Food and Drug Administration Safety and Innovation Act, as amended. This bill would reauthorize the FDA prescription drug and medical device user fee programs (which would otherwise expire on September 30, 2012), create new user fee programs for generic and biosimilar drug approvals, and make other revisions to other FDA drug and device approval processes. It reflects bicameral compromise on earlier versions of the bill (S. 3187 [ES], which passed the Senate on May 24, 2012, and H.R. 5651 [EH], which passed the House on May 30, 2012). The following CRS reports provide overview information on FDA's processes for approval and regulation of drugs: CRS Report R41983, How FDA Approves Drugs and Regulates Their Safety and Effectiveness, by Susan Thaul; CRS Report RL33986, FDA's Authority to Ensure That Drugs Prescribed to Children Are Safe and Effective, by Susan Thaul; CRS Report R42130, FDA Regulation of Medical Devices, by Judith A. Johnson; CRS Report R42508, The FDA Medical Device User Fee Program, by Judith A. Johnson. (Note: The rest of this report has not been updated since November 10, 2011.) With the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), Congress authorized the Food and Drug Administration (FDA) to offer drug manufacturers financial and regulatory incentives to test their products for use in children. Congress extended both programs with the FDA Amendments of 2007 (FDAAA) and, because of the programs' sunset date, must act before October 1, 2012, to continue them. This report presents the historical development of BPCA and PREA, their rationale and effect, and FDAAA's impact. The report also discusses pediatric drug issues that remain of concern to some in Congress. Most prescription drugs have never been the subject of studies specifically designed to test their effects on children. In these circumstances, clinicians, therefore, may prescribe drugs for children that FDA has approved only for adult use; this practice is known as off-label prescribing. Although some clinicians may believe that the safety and effectiveness demonstrated with adults would hold for younger patients, studies show that the bioavailability of drugs—that is, how much gets into a patient's system and is available for use—varies in children for reasons that include a child's maturation and organ development and other factors. The result of such off-label prescribing may be that some children receive ineffective drugs or too much or too little of potentially useful drugs; or that there may be side effects unique to children, including effects on growth and development. Drug manufacturers are reluctant to test drugs in children because of economic, ethical, legal, and other obstacles. Market forces alone have not provided manufacturers with sufficient incentives to overcome these obstacles. BPCA and PREA represent attempts by Congress to address the need for pediatric testing. FDA had tried unsuccessfully to spur pediatric drug research through administrative action before 1997. With the FDA Modernization Act of 1997 (FDAMA, P.L. 105-115), Congress provided an incentive: if a manufacturer completed pediatric studies that FDA requested, the agency would extend the company's market exclusivity for that product for six months, not approving the sale of another manufacturer's product during that period. In 2002, BPCA (P.L. 107-109) reauthorized this program for five years. In 1998, to obtain pediatric use information on the drugs that manufacturers were not studying, FDA published the Pediatric Rule, which required manufacturers to submit pediatric testing data at the time of all new drug applications.

Author:
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages :

View

Book Description

Author: New Zealand. Ministry of Health
Publisher:
ISBN: 9780478239348
Category : Drugs
Languages : en
Pages : 18

View

Book Description